| Chronic Obstructive Airway Disease
Ohtuvayre vs Yupelri
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Ohtuvayre vs Yupelri with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYupelri has a higher rate of injection site reactions vs Ohtuvayre based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yupelri but not Ohtuvayre, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ohtuvayre
Yupelri
At A Glance
Oral inhalation
Twice daily
PDE3/PDE4 inhibitor
Inhaled (nebulizer)
Once daily
Long-acting muscarinic antagonist
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
Dosing
Chronic Obstructive Airway Disease 3 mg (one unit-dose ampule) twice daily, once in the morning and once in the evening, via oral inhalation using a standard jet nebulizer with a mouthpiece.
Chronic Obstructive Airway Disease 175 mcg (one unit-dose vial) inhaled once daily via standard jet nebulizer with mouthpiece.
Contraindications
- Hypersensitivity to ensifentrine or any component of this product
- Hypersensitivity to revefenacin or any component of this product
Adverse Reactions
Most common (>=1%) Back pain, hypertension, urinary tract infection, diarrhea
Serious Paradoxical bronchospasm, psychiatric events including suicidality
Most common (>=2%) Cough, nasopharyngitis, upper respiratory tract infection, headache, back pain
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention, immediate hypersensitivity reactions
Postmarketing Dry mouth
Pharmacology
Ensifentrine is a dual inhibitor of PDE3 and PDE4 enzymes; inhibition results in accumulation of intracellular cAMP and/or cGMP, producing downstream bronchodilatory and anti-inflammatory signaling effects.
Revefenacin is a long-acting muscarinic antagonist (anticholinergic) that competitively and reversibly inhibits M3 receptors at airway smooth muscle, leading to bronchodilation predominantly through a site-specific effect following inhalation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ohtuvayre
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Yupelri
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (4/12)
UnitedHealthcare
Ohtuvayre
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Yupelri
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Ohtuvayre
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Yupelri
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Chronic Obstructive Pulmonary Disease (COPD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Chronic Obstructive Pulmonary Disease (COPD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OhtuvayreView full Ohtuvayre profile
YupelriView full Yupelri profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.